- Home
- LFUS vs ACLX Comparison
LFUS vs ACLX Comparison
Compare LFUS & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFUS | ACLX |
|---|---|---|
| Founded | 1927 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.7B |
| IPO Year | 1996 | 2022 |
Fundamental Metrics
Financial Performance| Metric | LFUS | ACLX |
|---|---|---|
| Price | $382.31 | $114.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 15 |
| Target Price | ★ $343.33 | $115.85 |
| AVG Volume (30 Days) | 212.5K | ★ 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $757,853,000.00 | $22,286,000.00 |
| Revenue This Year | $14.61 | $411.22 |
| Revenue Next Year | $7.02 | $138.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $149.51 | $47.86 |
| 52 Week High | $378.99 | $114.94 |
Technical Indicators
Market Signals| Indicator | LFUS | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 80.65 |
| Support Level | $241.48 | $66.06 |
| Resistance Level | N/A | $114.88 |
| Average True Range (ATR) | 13.88 | 0.20 |
| MACD | 4.84 | -1.21 |
| Stochastic Oscillator | 95.40 | 80.00 |
Price Performance
Historical ComparisonAbout LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. The company is also increasing its power semiconductor business, where it predominantly serves industrial end markets, and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.